Home › Peripheral Nerve Disorders › NCT07064798

Cryocompression for CIPN

Evaluating the Use of Limb Cryocompression to Reduce Taxane-induced Peripheral Neuropathy

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Adults \> 18 years of age
* Gynecologic or breast malignancy
* Starting 1st cycle of treatment with chemotherapy regimens:

  * Weekly paclitaxel x 12 or weekly paclitaxel/carboplatin x 12, Q2 weeks paclitaxel X4 (preceded by doxorubicin/cyclophosphamide). (Breast Oncology)
  * Q3 weeks paclitaxel/carboplatin X 6-8 (GYN)
* Receiving treatment on the main campus of DFCI (these patients are currently seen on Yawkey 9 and 10 and at Chestnut Hill)
* Able to complete questionnaires in English or Spanish

Exclusion Criteria:

* Previous exposure to neurotoxic chemotherapy
* Pre-existing neuropathy
* History of Raynaud's phenomenon, cold agglutinin disease, cryoglobulinemia, cryofibrinogenemia, post-traumatic cold dystrophy, peripheral arterial ischemia, or sickle cell disease
* Undergoing desensitization
* Lymphedema in the limb where the device would be applied
* Open skin wounds or ulcers of the limbs where the device would be applied

About the study

This study aims to evaluate the effectiveness, tolerability, and safety of using cooling therapy and pressure (cryocompression) to reduce peripheral neuropathy, a condition affecting the nerves supplying the arms and legs (limbs) resulting in possible numbness, pain, and/or loss of motor function, that may occur as a result of taxane-based chemotherapy.

The name of the device used in this research study is:

-Paxman Limb Cryocompression System (PLCS)

What is being tested

• Paxman Limb Cryocompression System (device)

Sponsor: Dana-Farber Cancer Institute · Participants: 50 · Started: Oct 22, 2025

Contact the study team

• Theresa Jabaley Leonarczyk, PhD, RN · Phone: 617-582-8037
• Jabaley Leonarczyk, PhD, RN · Phone: 617-582-8037

Official record on ClinicalTrials.gov — NCT07064798

Locations in the U.S.

Conditions

• Peripheral Nerve Disorders

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.